0
Research
Status of diabetes care among community pharmacy patients with diabetes: Analysis of the Medical Expenditure Panel Survey
Junling Wang, PhD; Jeremy Thomas, PharmD; Debbie Byrd, PharmD; Kamala Nola, PharmD, MS; Jing Liu, MD, PhD
J Am Pharm Assoc (2003) 2010;50:478-484. doi:10.1331/JAPhA.2010.08173

Abstract

Objective  To determine the status of diabetes care among community pharmacy patients with diabetes.

Design  Cross-sectional observational study.

Setting  United States, 2005.

Patients  1,455 community pharmacy patients aged 18 years or older with diabetes who were diagnosed before 2005.

Intervention  Analysis of the Medical Expenditure Panel Survey.

Main outcome measures  Proportions of patients meeting American Diabetes Association (ADA) standards of medical care in diabetes.

Results  In 2005, 1,455 patients with diabetes who were diagnosed before 2005 filled prescriptions through community pharmacies. Gaps occurred between the diabetes care of these patients and ADA standards. Examples include the following: ADA recommends at least two glycosylated hemoglobin (A1C) tests annually, but 19.52% of the study population reported less than two A1C tests in 2005; ADA recommends annual influenza vaccinations, but 42.46% of the study population reported not receiving an influenza vaccination in 2005; and ADA recommends weight control, but 83.74% of the study population was overweight or obese.

Conclusion  The current results demonstrate that many patients with diabetes are not receiving adequate care and that pharmacists have an opportunity to improve diabetes management.

Sign In
APhA Members 
Welcome to JAPhA.org! Please log in below using your APhA username and password. Update your APhA profile.
Not a Subscriber
New to JAPhA? Become an APhA member to receive a full subscription to both the print and online editions.

OR

Register for a FREE limited account to benefit from personalization features such as alerts.

References

Cioffi ST, Caron MF, Kalus JS, et al. Glycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic.  Ann Pharmacother. 2004;38:771–5.[PubMed][CrossRef]
 
 Centers for Disease Control and Prevention. Crude and age-adjusted prevalence of diagnosed diabetes per 100 population, United States, 1980–2005. Accessed at www.cdc.gov/diabetes/statistics/prev/national/figage.htm, November 18,  2008.
 
 American Diabetes Association. Economic costs of diabetes in the U.S. in 2007.  Diabetes Care. 2008;31:596–615.[PubMed]
 
 American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997.  Diabetes Care. 1998;21:296–309.[PubMed]
 
Armor BL, Britton ML.  Diabetes mellitus non-glucose monitoring: point-of-care testing.  Ann Pharmacother. 2004;38:1039–47.[PubMed]
 
 American Diabetes Association. Standards of medical care in diabetes.  Diabetes Care. 2005;28(suppl 1):S4–36.[PubMed]
 
Saaddine JB, Engelgau MM, Beckles GL, et al. A diabetes report card for the United States: quality of care in the 1990s.  Ann Intern Med. 2002;136:565–74.[PubMed]
 
Fera T, Bluml BM, Ellis WM, et al. The Diabetes Ten City Challenge: interim clinical and humanistic outcomes of a multisite community pharmacy diabetes care program.  J Am Pharm Assoc. 2008;48:181–90.
 
 Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.  N Engl J Med. 1993;329:977–86.[PubMed]
 
 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes.  Lancet. 1998;352:837–53.[PubMed]
 
Cranor CW, Christensen DB.  The Asheville Project: short-term outcomes of a community pharmacy diabetes care program.  J Am Pharm Assoc. 2003;43:149–59.
 
Cranor CW, Bunting BA, Christensen DB.  The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program.  J Am Pharm Assoc. 2003;43:173–84.
 
Brooks AD, Rihani RS, Derus CL.  Pharmacist membership in a medical group's diabetes health management program.  Am J Health Syst Pharm. 2007;64:617–21.[PubMed]
 
Martin OJ, Wu WC, Taveira TH, et al. Multidisciplinary group behavioral and pharmacologic intervention for cardiac risk reduction in diabetes: a pilot study.  Diabetes Educ. 2007;33:118–27.[PubMed]
 
Scott DM, Boyd ST, Stephan M, et al. Outcomes of pharmacist-managed diabetes care services in a community health center.  Am J Health Syst Pharm. 2006;63:2116–22.[PubMed]
 
Wubben DP, Vivian EM.  Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review.  Pharmacotherapy. 2008;28:421–36.[PubMed]
 
Shane-McWhorter L, Fermo JD, Bultemier NC, Oderda GM.  National survey of pharmacist certified diabetes educators.  Pharmacotherapy. 2002;22:1579–93.[PubMed]
 
McClellan MB.  Testimony of Mark B. McClellan, MD, PhD, Administrator, Centers for Medicare & Medicaid Services, before the House Committee on Energy and Commerce Subcommittee on Health Hearing on Implementation of the Medicare Prescription Drug Benefit. Accessed at www.cms.gov/hearingstestimony/downloads/testimonyfinal3.1.06.pdf, May 22,  2010.
 
 Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. Accessed at www.meps.ahrq.gov/mepsweb, March 15,  2008.
 
 American Diabetes Association. Standards of medical care in diabetes–2008.  Diabetes Care. 2008;31(suppl 1):S12–54.[PubMed]
 
Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetes and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analysis in the Cholesterol and Recurrent Events (CARE) trial.  Circulation. 1998;98:2513–9.[PubMed]
 
Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes progress of care and intermediate outcomes: United States, 1998-2002.  Ann Intern Med. 2006;144:465–74.[PubMed]
 
Garrett DG, Bluml BM.  Patient self-management program for diabetes: first-year clinical, humanistic, and economic outcomes.  J Am Pharm Assoc. 2005;45:130–7.
 
Stagnitti MN.  Statistical Brief #200: comparing population characteristics of persons purchasing prescribed drugs from mail order pharmacies with persons purchasing prescribed drugs from other outlets, 2005. Accessed at www.meps.ahrq.gov/mepsweb/data_files/publications/st200/stat200.pdf, November 18,  2008.
 
Kalsekar I, Sheehan C, Peak A. Utilization patterns and medication adherence in patients with type 2 diabetes: variation based on type of pharmacy (chain vs. independent).  Res Social Adm Pharm. 2007;3:378–91.[PubMed]
 
Campbell RK.  Role of the pharmacist in diabetes management.  Am J Health Syst Pharm. 2002;59(suppl 9):S18–21.[PubMed]
 
 Agency for Healthcare Research and Quality. National Healthcare Disparities Report, 2005. Accessed at www.ahrq.gov/qual/nhdr05/nhdr05.htm, November 18,  2008.
 
 Agency for Healthcare Research and Quality. National Healthcare Quality Report, 2005. Accessed at www.ahrq.gov/qual/nhqr05/nhqr05.htm, November 18,  2008.
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Please read the other comments before you post yours. Comments are moderated and will appear on the site at the discertion of the editorial staff.
* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content

Customize your page view by dragging & repositioning the boxes below.

JAPhA Articles
Topic Collections
PubMed Articles
Advertisement
 
  • Print
  • PDF Download
  • Email
  • Share
  • Get Citation
  • Submit Comment
  • Article Alerts
    Please Wait... Processing your request... Please Wait.
    You must sign in to sign-up for alerts.

    Please confirm that your email address is correct, so you can successfully receive this alert.

  • Letters To Editor
  • Reprints